Business Wire

CA-SYNACK

Share
Finally, Smart Cybersecurity: The Optimal Combination of Ethical Hackers and Artificial Intelligence

The debate on how we should best use Artificial Intelligence is ongoing, but no one can argue against its benefits when used to augment human work. Take self-driving cars: when Artificial Intelligence is used alongside humans, it provides features like improved safety and predictive driving. The same is true in cybersecurity; we will always need the creativity of human intelligence to beat the human adversary. However, we can also augment those humans with smart technology to help make them more effective, cover a wider attack surface, and speed up their time to find and fix vulnerabilities. Synack, the trusted leader in crowdsourced security, has just launched the industry’s first cybersecurity platform to integrate crowdsourced human intelligence augmented with artificial intelligence to help security teams work smarter, not harder, to protect digital assets continuously and at scale.

The impact? Intelligence that helps security teams find and fix vulnerabilities faster and build more secure code.

The stakes are high - cybercrime is predicted to cost the world $6 trillion annually by 2021- and human capital to protect the cybersphere is lacking; 3.5 million cybersecurity jobs are predicted to go unfilled by 2021 (Cybersecurity Ventures).

“While humans can’t scale, machines can’t think. More than 80% of the vulnerabilities that our Synack Red Team find in our clients’ assets aren’t detected by a scanner. We will always need the creativity of human intelligence. But to scale at the pace of the threats, we need to automate wherever possible and keep building technology to test ‘smarter’,” Dr. Mark Kuhr, Synack CTO and co-founder said.

Synack’s industry-leading cybersecurity Platform 2.0 delivers a smarter, more efficient security test through the use of smart platform technology and new product, SmartScan. Together, the platform’s new features and advanced technology seamlessly orchestrate the optimal combination of human and machine intelligence for more effective, efficient security on a 24/7/365 basis. SmartScan helps security teams increase their attack surface coverage and gain new insight by continuously scanning for suspected vulnerabilities and engaging the company’s crowdsourced network of ethical hackers to validate them. The augmented intelligence offered by Synack’s “smart” Crowdsourced Security Platform, if applied to all penetration testing, would add 4x more efficiency to security teams.

Additional benefits of Synack’s Crowdsourced Security Platform to security teams include:

  • Noise Reduction: 99.98% of total noise is reduced by leveraging Synack SmartScan in combination with Synack Red Team crowdsourced vulnerability triage and patch verification services.
  • Higher Value: The latest version of Synack’s platform with augmented intelligence increases the ROI of Synack’s original offering by over 50%. Customers will see a 159% ROI with the Synack Crowdsourced Security Platform in comparison to a traditional penetration test. And if comparing the Synack platform to a traditional scanner, they will get a 262% ROI. If deployed universally across application security testing, SmartScan would add ~$3B in security value back to the market.

In addition to SmartScan, Synack’s Crowdsourced Security Platform 2.0 includes other new and enhanced features; Apollo, a machine learning and automation engine that optimizes the integration of humans and technology, superior analytics and reporting, and LaunchPoint+, a secure testing gateway with added researcher endpoint control and enhanced workspaces to support privacy for highly regulated environments. Synack Red Team researchers said they were “happy with the [LaunchPoint+] concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot” in response to Synack launching the only crowdsourced security testing with endpoint control baked into the platform.

About Synack

Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .

Contact:

Ellie McCardwell, Synack Communications press@synack.com

Link:

ClickThru

Social Media:

https://www.facebook.com/synack/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release

Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e

Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release

News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye